Company: LGNZZ
Filing Date: 2025-02-25
Form Type: 8-K
Source: 0000886163-25-000003
Chunk: 1

Company: LIGAND PHARMACEUTICALS INC
Filing Date: 2025-02-25
Form: 8-K
Item: Item 7.01
Chunk 1
---
Item 7.01 Regulation FD Disclosure.

On February 25, 2025, Ligand issued a press release announcing its entry into the Agreement. A copy of the press release is furnished herewith as Exhibit 99.1 to this report.

In accordance with General Instruction B.2. of Form 8-K, the information in this Item 7.01 of this report, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.